ClinicalTrials.gg
RecruitingNCT07707895Updated Nov 12, 2026

DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers

A Phase 1/2 interventional study of Obrixtamig and ZL-1310 in Small Cell Lung Cancer, Large Cell Neuroendocrine Lung Carcinoma and Extrapulmonary Neuroendocrine Carcinoma of Small Cell Histology, sponsored by Boehringer Ingelheim. Recruiting at 28 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Boehringer Ingelheim · Phase 1/2, Interventional, and Treatment

Updated Nov 12, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 78 studies in Small Cell Lung Carcinoma with a site in Japan — 27 open to participants now, 44 under way, 18 of them phase 3. Small Cell Lung Carcinoma · Japan.

Planned enrollment
60th of 76
60 · median 240
Started
2026
with 8 others
Phase 1/2
9 of 78
8 open now
Primary completion
2030-04
later than 35 of 43 live
Registered
75th of 78
by date
Lead sponsor
7 of 78
Boehringer Ingelheim

Among the 78 studies in Small Cell Lung Carcinoma with a site in Japan, this one is the 60th largest by planned enrollment of the 76 interventional ones that give a count, is one of 9 that started in 2026, is one of 9 in phase 1/2, reaches primary completion later than 35 of the 43 other live ones, and was the 75th registered.

Small Cell Lung Carcinoma

1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

27 of the 78 studies in Small Cell Lung Carcinoma with a site in Japan are open now. Recruiting first, the newest first:

21 more — sign in →

All 27 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 78 studies in Small Cell Lung Carcinoma with a site in Japan, or all of them as a file.
02

Study summary

This study is open to adults with advanced small cell lung cancer and other neuroendocrine cancers. The study has 2 parts. The purpose of Part 1 is to find a suitable dose of a combination study treatment, obrixtamig and ZL-1310. The purpose of Part 2 is to see how obrixtamig and ZL-1310 is tolerated when given with another medicine called a checkpoint inhibitor. Another purpose is to check whether the study treatment can stop the cancer from growing and keep it stable. Obrixtamig and ZL-1310 are being developed to help the immune system fight cancer.

In Part 1, participants get obrixtamig and ZL-1310. In Part 2, participants get obrixtamig and ZL-1310 with a checkpoint inhibitor. Part 2 is only open to people with advanced small cell lung cancer. All study treatments are given as infusions into a vein.

The study does not have a fixed duration. Participants can receive study treatment for up to 2 years if they benefit from treatment and can tolerate it. Participants visit the study site regularly, with some overnight stays required. During this time, doctors regularly check for health problems that could be caused by the study treatment. They also monitor the size of the tumour(s) and take laboratory tests.

03

Conditions studied

  • Small Cell Lung Cancer
  • Large Cell Neuroendocrine Lung Carcinoma
  • Extrapulmonary Neuroendocrine Carcinoma of Small Cell Histology
  • Extrapulmonary Neuroendocrine Carcinoma of Large Cell Histology
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For Part 1

  1. Diagnosed with locally advanced, or cancer of the following histologies:

    • Small cell lung carcinoma (SCLC)
    • Large cell neuroendocrine lung carcinoma (LCNEC-L)
    • Extrapulmonary neuroendocrine carcinoma (epNEC) of small or large cell histology
  2. Patients with tumours with mixed histologies for any above type are eligible only if the neuroendocrine carcinoma/small cell component is predominant and represents at least 50% of the overall tumour tissue
  3. Patients for whom no therapy of proven efficacy exists or who are not eligible for established treatment options. Patients must have exhausted available treatment options known to prolong survival for their disease. Previous therapies should include at least one line of platinum-based chemotherapy, unless there is a documented medical reason not to use platinum

    For Part 2

  4. or cytologically confirmed extended stage small cell lung cancer (ES-SCLC) (excluding combined histologies) using the American Joint Committee on Cancer (AJCC) tumour node metastasis staging system combined with Veterans Administration Lung Study Group (VALG)'s two stage classification scheme.
  5. Patients must have received no prior systemic therapy for ES-SCLC. Participants with prior chemoradiotherapy for Limited stage small cell lung cancer (LS-SCLC) must have been treated with curative intent and had a treatment-free interval of at least 6 months after the last chemotherapy, radiotherapy, or chemoradiotherapy before diagnosis of ES-SCLC to be eligible

    For both Part 1 and Part 2

  6. Signed and dated written in accordance with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use - Good Clinical Practice (ICH-GCP) and local legislation prior to any trial-specific procedures, sampling, or analyses
  7. Male or female participants ≥18 years old and at least at the legal age of consent in countries where it is greater than 18 years at the time of signature of the informed consent form (ICF)
  8. Willing and able to comply with scheduled visits, treatment schedule, the planned trial assessments, laboratory tests, restrictions regarding prohibited medications, lifestyle restrictions, and other requirements related to the trial. This includes that they are able to understand and follow trial-related instructions
  9. Further inclusion criteria apply.

Exclusion criteria

Exclusion criteria:

  1. Serious concomitant disease or medical condition such as neurologic, psychiatric (including substance use disorder), active ulcers (gastrointestinal tract or skin) or laboratory abnormalities that may negatively impact patient safety during trial participation, affect compliance with trial requirements or invalidate assessments relevant for the investigation of the safety and preliminary efficacy of the drugs
  2. Patients with a diagnosis of Merkel cell carcinoma or medullary thyroid cancer
  3. Presence of and/or carcinomatous meningitis
  4. Known to the trial drugs or their , prior severe, life-threatening hypersensitivity reaction(s) to monoclonal antibodies, or significant risk of allergic or anaphylactic reaction(s) to any of the investigated drug products according to the investigator's judgement
  5. Participants who experienced severe, life-threatening immune-mediated adverse events, e.g. serious Grade 3 or higher immune-related adverse event (imAE) or infusion-related reactions, that led to permanent discontinuation while on treatment with immuno-oncology agents
  6. Persistent toxicity from previous treatments that has not resolved to ≤ (CTCAE) Grade 1 (except for alopecia, asthenia/fatigue, amenorrhea/menstrual disorders, CTCAE Grade 2 peripheral neuropathy, and CTCAE Grade 2 endocrinopathies controlled by replacement therapy, and toxicities, which are considered irreversible but stable for at least 4 weeks, per investigator judgment)
  7. Therapy with any of the following types of treatments or drugs within the noted time intervals prior to IMP administration: At any time: treatment with delta-like ligand 3 (DLL3)-targeting therapies or received more than 30 Gy of thoracic radiotherapy.
  8. Prior organ or tissue allograft
  9. Further exclusion criteria apply.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Part 1: obrixtamig + ZL-1310 (dosing regimen 1)

    Drug: Obrixtamig · Drug: ZL-1310

  • Experimental
    Part 1: obrixtamig + ZL-1310 (dosing regimen 2)

    Drug: Obrixtamig · Drug: ZL-1310

  • Experimental
    Part 2: obrixtamig + ZL-1310 + atezolizumab

    Drug: Obrixtamig · Drug: ZL-1310 · Drug: Atezolizumab

Interventions

06

What researchers measure

Primary outcomes

  1. Part 1: The occurrence of dose limiting toxicities (DLTs) during the DLT evaluation period

    Time frame: 6 weeks from the first administration of study medication.

  2. Part 2: The occurrence of treatment-emergent adverse events (AEs) leading to trial medication discontinuation or dose modification

    Time frame: Up to 24 months.

  3. Part 2: PFS rate at 6 months

    Progression-free survival (PFS) is defined as the time from first investigational medicinal product (IMP) administration until the earliest date of disease progression according to Response Evaluation Criteria In Solid Tumours (RECIST 1.1) based on investigator assessments or death from any cause, whichever occurs first.

    Time frame: At 6 months.

Secondary outcomes

  1. Part 1 and Part 2: Occurrence of treatment-emergent DLTs

    Time frame: Up to 24 months.

  2. Part 1 and Part 2: Occurrence of treatment-emergent adverse event of special interest (AESIs)

    Time frame: Up to 24 months.

  3. Part 1 and Part 2: Occurrence of treatment-emergent AEs CTCAE Grade ≥3

    AEs CTCAE = Adverse events Common Terminology Criteria for Adverse Events

    Time frame: Up to 24 months.

  4. Part 1 and Part 2: Objective response (OR)

    OR is defined as a best overall response of confirmed complete response (CR) or confirmed partial response (PR) according to RECIST 1.1 (based on investigator assessments) from the first IMP administration until the earliest date of disease progression, death, last evaluable tumour assessment before the start of the next line of anti-cancer treatment, loss to follow-up, or withdrawal of consent.

    Time frame: Up to 24 months.

  5. Part 1 and Part 2: Duration of response (DoR)

    DoR is defined as the time from the first documented objective response (OR) according to RECIST 1.1 until the earliest date of disease progression or death among patients with confirmed objective response based on investigator assessments.

    Time frame: Up to 24 months.

  6. Part 1 and Part 2: Disease control (DC)

    DC is defined as best overall response of complete response (CR) or partial response (PR) or stable disease (SD) where best overall response is defined according to RECIST version 1.1 based on investigator assessments from the first IMP administration until the earliest date of disease progression, death or last evaluable tumour assessment before start of the next line of anti-cancer treatment, loss to follow-up or withdrawal of consent.

    Time frame: Up to 24 months.

  7. Part 1: Progression-free survival (PFS)

    PFS is defined as the time from first IMP administration until the earliest date of disease progression according to RECIST 1.1 based on investigator assessments or death from any cause, whichever occurs first.

    Time frame: Up to 24 months.

  8. Part 2: Occurrence of DLTs during the DLT evaluation period

    Time frame: 6 weeks from the first administration of study medication.

07

Study locations

5 of 28 sites recruiting
08

References and documents

Related links

Individual participant data

Plan to share: Yes — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization). For more details refer to: https://www.clinicalstudies.boehringer-ingelheim.com/msw/datasharing

Supporting information: Statistical analysis plan, Informed consent form, Clinical study report

Time frame: One year after the approval has been granted by major Regulatory Authorities and after the primary manuscript has been accepted for publication, or after termination of the development program.

Access criteria: For study documents -upon signing of a 'Document Sharing Agreement'. For study data -1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement.

Data sharing details ↗ · www.clinicalstudies.boehringer-ingelheim.com

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2026 (actual). Primary completion is estimated for Apr 2030, 41 months after the start.

Of 71 industry-sponsored phase 1/2 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 74. This study's planned 41 months is below that.

Counting every sponsor, half of 98 studies reached it within 54 months; a quarter within 44 and three quarters within 97.

Start moved 3 times since we started tracking on Sep 25, 2026: Sep 2026 → Nov 2026, last on Nov 12, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2026
First posted
Jul 16, 2026
StartActual
Nov 3, 2026was Sep 2026
Primary completionEst.
Apr 26, 2030
CompletionEst.
Apr 26, 2030
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 12, 2026
Sites
2 sites added, 1 site removed. 27 sites changed recruiting status (22 now not yet recruiting, 5 now recruiting)
Show 27 sites
  • MedStar Georgetown University Hospital · Washington D.C., United Statesno status→Not yet recruiting
  • H. Lee Moffitt Cancer Center and Research Institute · Tampa, United Statesno status→Not yet recruiting
  • University of Kentucky Medical Center · Lexington, United Statesno status→Recruiting
  • Chris Obrien Lifehouse · Camperdown, Australiano status→Not yet recruiting
  • Royal North Shore Hospital · St Leonards, Australiano status→Not yet recruiting
  • Universitair Ziekenhuis Antwerpen · Edegem, Belgiumno status→Not yet recruiting
  • Universitair Ziekenhuis Gent · Ghent, Belgiumno status→Not yet recruiting
  • The Affiliated Cancer Hospital, Guangxi Medical University · Nanning, Chinano status→Not yet recruiting
  • Shanghai Chest Hospital · Shanghai, Chinano status→Not yet recruiting
  • Shanghai Pulmonary Hospital · Shanghai, Chinano status→Not yet recruiting
  • CTR Leon Berard · Lyon, Franceno status→Not yet recruiting
  • HOP Timone · Marseille, Franceno status→Not yet recruiting
  • Institut Gustave Roussy · Villejuif, Franceno status→Not yet recruiting
  • Universitätsmedizin der Johannes Gutenberg-Universität Mainz · Mainz, Germanyno status→Not yet recruiting
  • Robert Bosch Gesellschaft für medizinische Forschung mbH · Stuttgart, Germanyno status→Recruiting
  • Hokkaido Cancer Center · Hokkaido, Sapporo, Japanno status→Not yet recruiting
  • St. Marianna University Hospital · Kanagawa, Kawasaki, Japanno status→Not yet recruiting
  • Kansai Medical University Hospital · Osaka, Hirakata, Japanno status→Not yet recruiting
  • Shizuoka Cancer Center · Shizuoka, Sunto-gun, Japanno status→Not yet recruiting
  • Amsterdam UMC Locatie VUMC · Amsterdam, Netherlandsno status→Not yet recruiting
  • Szpital Specjalistyczny W Brzozowie Podkarpacki Osrodek Onkologiczny Im.Ks.B.Markiewicza · Brzozów, Polandno status→Not yet recruiting
  • Lower Silesian Oncology Centre · Wroclaw, Polandno status→Not yet recruiting
  • Hospital Duran i Reynals · L'Hospitalet Del Llobregat, Spainno status→Recruiting
  • Hospital Universitario 12 de Octubre · Madrid, Spainno status→Recruiting
  • Hospital Clinico De Valencia (INCLIVA) · Valencia, Spainno status→Recruiting
  • Leicester Royal Infirmary · Leicester, United Kingdomno status→Not yet recruiting
  • Freeman Hospital · Newcastle upon Tyne, United Kingdomno status→Not yet recruiting
Show 2 added (1 Australia, 1 Poland)
  • Royal North Shore Hospital · St Leonards, Australia
  • Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy · Warsaw, Poland
Show 1 removed
  • Northwestern University · Chicago, United States
across 2 updates, Oct 27, 2026 – Nov 12, 2026
Start date
Sep 29, 2026→Nov 3, 2026 (actual)
moved 3 times, Sep 29, 2026 – Nov 12, 2026
Show all 3 updates
  1. Nov 12, 2026
    Not yet recruiting→Recruiting
    1 site added. 27 sites changed recruiting status (22 now not yet recruiting, 5 now recruiting)
    Show 27 sites
    • MedStar Georgetown University Hospital · Washington D.C., United Statesno status→Not yet recruiting
    • H. Lee Moffitt Cancer Center and Research Institute · Tampa, United Statesno status→Not yet recruiting
    • University of Kentucky Medical Center · Lexington, United Statesno status→Recruiting
    • Chris Obrien Lifehouse · Camperdown, Australiano status→Not yet recruiting
    • Royal North Shore Hospital · St Leonards, Australiano status→Not yet recruiting
    • Universitair Ziekenhuis Antwerpen · Edegem, Belgiumno status→Not yet recruiting
    • Universitair Ziekenhuis Gent · Ghent, Belgiumno status→Not yet recruiting
    • The Affiliated Cancer Hospital, Guangxi Medical University · Nanning, Chinano status→Not yet recruiting
    • Shanghai Chest Hospital · Shanghai, Chinano status→Not yet recruiting
    • Shanghai Pulmonary Hospital · Shanghai, Chinano status→Not yet recruiting
    • CTR Leon Berard · Lyon, Franceno status→Not yet recruiting
    • HOP Timone · Marseille, Franceno status→Not yet recruiting
    • Institut Gustave Roussy · Villejuif, Franceno status→Not yet recruiting
    • Universitätsmedizin der Johannes Gutenberg-Universität Mainz · Mainz, Germanyno status→Not yet recruiting
    • Robert Bosch Gesellschaft für medizinische Forschung mbH · Stuttgart, Germanyno status→Recruiting
    • Hokkaido Cancer Center · Hokkaido, Sapporo, Japanno status→Not yet recruiting
    • St. Marianna University Hospital · Kanagawa, Kawasaki, Japanno status→Not yet recruiting
    • Kansai Medical University Hospital · Osaka, Hirakata, Japanno status→Not yet recruiting
    • Shizuoka Cancer Center · Shizuoka, Sunto-gun, Japanno status→Not yet recruiting
    • Amsterdam UMC Locatie VUMC · Amsterdam, Netherlandsno status→Not yet recruiting
    • Szpital Specjalistyczny W Brzozowie Podkarpacki Osrodek Onkologiczny Im.Ks.B.Markiewicza · Brzozów, Polandno status→Not yet recruiting
    • Lower Silesian Oncology Centre · Wroclaw, Polandno status→Not yet recruiting
    • Hospital Duran i Reynals · L'Hospitalet Del Llobregat, Spainno status→Recruiting
    • Hospital Universitario 12 de Octubre · Madrid, Spainno status→Recruiting
    • Hospital Clinico De Valencia (INCLIVA) · Valencia, Spainno status→Recruiting
    • Leicester Royal Infirmary · Leicester, United Kingdomno status→Not yet recruiting
    • Freeman Hospital · Newcastle upon Tyne, United Kingdomno status→Not yet recruiting
    Show site
    • Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy · Warsaw, Poland
    Start date Oct 28, 2026→Nov 3, 2026 (now actual)
    + 1 other change: verification date
  2. Oct 27, 2026
    1 site added, 1 site removed
    Show site
    • Royal North Shore Hospital · St Leonards, Australia
    Show 1 removed
    • Northwestern University · Chicago, United States
    Start date Oct 19, 2026→Oct 28, 2026
    + 1 other change: verification date
  3. Sep 29, 2026
    Start date Sep 29, 2026→Oct 19, 2026

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07707895
Collaborators
Zai Lab
Responsible party
Sponsor
First posted
Jul 16, 2026
Start date
Nov 3, 2026
Primary completion
Apr 26, 2030 (estimated)
Completion
Apr 26, 2030 (estimated)
Last update
Nov 12, 2026

Study contacts

Boehringer Ingelheim
Contact
clintriage.rdg@boehringer-ingelheim.com
1-800-243-0127

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Obrixtamig · Zocilurtatug Pelitecan

Start the discussion